Intellia Therapeutics (NTLA) Current Deferred Revenue (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Current Deferred Revenue data on file, last reported at $630000.0 in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 98.14% year-over-year to $630000.0 in Q1 2026; TTM through Mar 2026 was $630000.0, a 98.14% decrease from a year earlier, with the FY2025 full-year figure at $7.3 million, down 81.27% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $630000.0, down from $7.3 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for NTLA reached as high as $113.2 million in Q1 2022 and fell as low as $630000.0 in Q1 2026.
• Historically, Current Deferred Revenue has averaged $47.7 million across 5 years, with a median of $44.8 million in 2024.
• Across the five-year window, Current Deferred Revenue surged 71.73% in 2024 and tumbled 98.14% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $63.8 million in 2022, then dropped by 4.36% to $61.0 million in 2023, then plunged by 36.19% to $38.9 million in 2024, then tumbled by 81.27% to $7.3 million in 2025, then sank by 91.36% to $630000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $630000.0 in Q1 2026, $7.3 million in Q4 2025, and $24.8 million in Q3 2025.